Colon Cancer Pathological and Clinical Stages
Dr. Kozloff explains that although there are four specific stages of colon cancer, doctors often break the stages up into two stages: clinical and pathologic...

By: coloncancerdr

Excerpt from:
Colon Cancer Pathological and Clinical Stages - Video

Recommendation and review posted by Bethany Smith

JEFFREY BROWN: In California, researchers are sifting through a huge collection of genetic data that could be a key to unlocking vital information for doctors and patients.

NewsHour correspondent Spencer Michels reports.

SPENCER MICHELS: Every year, 240,000 men in America learn that they have prostate cancer. Reggie Watkins, a retired parole officer and a patient at Kaiser Permanente in Oakland, Calif., is one of them.

REGGIE WATKINS, Kaiser Patient: The first biopsy showed a slight cancer, slight amount of cancer. The second biopsy showed no cancer. I do think there's a genetic situation in my family. I'm not the only and my brother is not the only one in the family to have this problem.

SPENCER MICHELS: Until recently, Watkins' family history and his unique genetic makeup would have played a minor role, if any, in his medical care. But thanks in part to a massive, groundbreaking new study under way at Kaiser and the University of California, San Francisco, information gleaned from patients' genes may prove the key to identifying and treating a host of diseases.

NEIL RISCH, University of California, San Francisco: You know, you're not born to this world as a blank slate. You come into it with a certain genetic disposition.

SPENCER MICHELS: UCSF Professor Neil Risch, the lead genetic researcher, says that his project and others that compile vast amounts of genetic information are on the verge of revolutionizing medicine.

NEIL RISCH: We can actually look to see how the genes that somebody has and they have had since they were born interact with environmental factors that actually work together to either increase or decrease risk of, say, heart disease or cancer or a whole variety of things.

SPENCER MICHELS: More than 200,000 Kaiser patients in California over the last five years have volunteered saliva and blood samples for genetic analysis. Those samples are processed at this Kaiser lab using state-of- the-art robotic devices which extract the DNA.

CATHERINE SCHAEFER, Kaiser Permanente: This is the richest, largest, the most comprehensive data bank right now in the world.

Read the original post:
Researchers Aim to Unlock Genetic Data Goldmine for Vital Medical Information

Recommendation and review posted by Bethany Smith

Strange Materials with Mark Miodownik
Materials are a defining characteristic of society. The ages of civilization are named after materials and the development of new materials do more than simp...

By: TheRoyalInstitution

View original post here:
Strange Materials with Mark Miodownik - Video

Recommendation and review posted by Bethany Smith

Can You Build Muscle With Hardgainer Genetics
http://www.StackedNJacked.com - Click HERE for your FREE guide to getting Stacked N Jacked. http://dclaiborne.com/start-here - Click HERE for your FREE repor...

By: GenesisAthleticPerf

Visit link:
Can You Build Muscle With Hardgainer Genetics - Video

Recommendation and review posted by Bethany Smith

Debut DNA Genetics Exodus Kush
Debut of DNA Genetics Exodus Kush, taking some clones off this cute plant that is in the vegative phase. This Exodus Kush looks really healthy and I #39;m excite...

By: Matt Mernagh

Visit link:
Debut DNA Genetics Exodus Kush - Video

Recommendation and review posted by Bethany Smith

The Great Debate - What is Life?
http://www.thesciencenetwork.org Richard Dawkins, J. Craig Venter, Nobel laureates Sidney Altman and Leland Hartwell, Chris McKay, Paul Davies, Lawrence Krau...

By: TheScienceFoundation

Visit link:
The Great Debate - What is Life? - Video

Recommendation and review posted by Bethany Smith

15 hours ago Mar. 12, 2013 - 9:00 AM PDT

Spiral Genetics, a Seattle-based startup that helps researchers and others quickly analyze DNA sequence data, has raised $3 million in its first institutional round of funding.

The Series A round was led by venture firm DFJ and brings the startups total amount raised to $3.7 million. With the new funding, Adina Mangubat, Spiral Genetics co-founder and CEO, said her eight-person team plans to expand product development, as well as sales and marketing.

Mangubat said that when she and one of her co-founders, Becky Drees, first looked at the field of genomics, their plan was to launch a consumer-focused genetic testing service like 23andme. But as that company started launching its services, they decided to switch tacks.

We were looking at the industry and we wanted to do something really impactful that involved genomics and computing, she said. When they realized the speed and volume with which raw sequence data was being generated, she said, they spotted an opportunity in offering high-performance bioinformatics tools for analyzing it.

Companies like DNANexus also offer sequence analysis, and others might conduct the analysis in-house, but Mangubat said they envisioned a service that could shrink the turnaround time for researchers and others in industry deluged by data. Last month, Redwood City, Calif.-based Bina Technologies announced the commercial launch of its own genomic analysis platform and similarly touts a faster-than-ever service.

Mangubat and Drees teamed up with their third co-founder Jeremy Bruestle and started building a computing platform specifically intended to solve this kind of big data problem. Now, the company says, it can analyze a whole human genome in 3 hours, which is about 40 times faster than what it might take others.

Spiral Genetics customers run the gamut from academic researchers to corporations, Mangubat said. For example, while some clients may use their bioinformatics tool to tackle childhood cancer, others in agrigenomics could use it to sequence different strains of corn.

Along with the new funding, Spiral Genetics announced a new partnership with Omicia, an Emeryville, Calif.-based provider of clinical genome sequence interpretation tools.

Subscriber Content

Read more from the original source:
Big data bioinformatics startup Spiral Genetics raises $3M

Recommendation and review posted by Bethany Smith

LOS ANGELES, March 12, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today that Thomas A. Bologna, Chairman and CEO, will present at the 25th Annual ROTH Conference in Laguna Niguel, CA.

Mr. Bologna's presentation is scheduled to begin at 4:00 p.m. PDT on March 19, 2013. Interested investors can access a live webcast of the presentation by going to the Investor Relations tab on the Response Genetics website: http://www.responsegenetics.com.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit http://www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to strengthen marketing capabilities, to expand the suite of ResponseDX(R)products, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "project," "may," "could," "would," "should," "believe," "expect," "anticipate," "estimate," "intend," "plan" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Read this article:
Response Genetics to Present at the 25th Annual ROTH Conference

Recommendation and review posted by Bethany Smith

SEATTLE, March 12, 2013 /PRNewswire/ --Spiral Genetics, a cloud-based big data bioinformatics company, announced today that it closed its Series A financing, led by venture capital firm DFJ. The new capital will help further Spiral Genetics' mission to create revolutionary tools that empower the bioinformatics community to solve the large-scale genomic data challenges of tomorrow. The company intends to use the funds to expand its bioinformatics engineering team, scale its sales and marketing efforts and accelerate product development.

In addition to its funding, Spiral announced its partnership with Omicia, a developer of scalable and fully integrated informatics systems specifically designed to interpret human genome sequences for research and clinical applications. The partnership leverages Omicia's Opal solution which is a variant analysis tool that empowers researchers and clinicians to analyze genomes and prioritize disease-causing variants.

"Our partnership with Spiral Genetics allows faster and more accurate interpretation of human genomes for clinical relevance; a critical bottleneck for adoption of genomes into clinical care and laboratory testing. In combination with Omicia's Opal system, our partnership will move us closer to a seamless solution from raw sequence data to clinically relevant genomic variants. Speed and user friendliness are critical for adoption of human genome sequencing," stated Martin G. Reese, Ph.D, Co-Founder, President and Chief Scientific Officer Omicia. The Opal tool is used by CLIA labs and clinical researchers and in combination with Spiral's platform is providing same-day analysis from raw reads to produce clinically relevant findings.

"Innovations in DNA sequencing have led to an explosion of data, which presents an enormous market opportunity," said Rachel Pike of DFJ. "These developments are only accelerating and will have real and lasting implications on drug development, R&D in agriculture, and biological production of chemicals and fuels. Spiral Genetics is a solution that will both manage and draw insight from these data, enabling the industry to keep up with constantly-accelerating technological progress."

The Spiral Platform offers the fastest cloud-based bioinformatics analysis available today. Their breakthrough approach accelerates the data processing time from days to hours, shrinking analysis time for a whole human genome at 40x coverage to 3 hours.

"We are thrilled to be backed by DFJ," stated Adina Mangubat, CEO of Spiral Genetics. "DFJ has consistently invested in industry leaders whose technologies are changing critical industry sectors. As more academic researchers and agro-genomic and pharmaceutical companiesincrease their use of genomic data, there's no doubt that a large-scale, focused bioinformatics toolkit to process and analyze genomic data will be vital. We are excited to be at the forefront of developing new solutions to these challenges."

About Spiral Genetics Spiral Genetics provides the fastest cloud-based bioinformatics analysis available today. Used by customers across a variety of industries including drug development and agriculture, Spiral's breakthrough approach accelerates data processing time from days to hours, allowing researchers to analyze a whole human genome from raw DNA sequence data to a fully annotated list of genetic variants in just 3 hours.

About DFJ DFJ is a venture capital firm that partners with extraordinary entrepreneurs who set out to change the world. Since 1985, DFJ and the DFJ Global Network have had $7B committed to their funds and have managed more than 400 portfolio investments, including AdMob, Baidu, Box, Skype, Hotmail, SpaceX, Tesla Motors, SolarCity, Twitter, Tumblr and Yammer. DFJ works with companies at seed, early and growth stages, with the goal of creating iconic and lasting businesses. DFJ pioneers investing in emerging markets including consumer and enterprise information technology, digital media, and disruptive technologies. The DFJ Global Network is a federation of 16 independent venture funds operating on four continents that cooperate on investment diligence and co-investing. Learn more at dfj.com.

About Omicia, Inc. Based in the San Francisco Bay Area, Omicia develops scalable and fully integrated informatics systems specifically designed to interpret human genome sequences for research and clinical applications. Omicia's mission is to help research scientists, clinicians and patients better understand the most relevant information from personal genome sequences and their potential medical consequences. Omicia is funded with private investments and a series of Small Business Innovation Research (SBIR) grants from the National Institutes of Health. For more information, please visit http://www.omicia.com

Follow this link:
Spiral Genetics Closes $3 Million in Funding Led by DFJ and Announces Partnership with Omicia

Recommendation and review posted by Bethany Smith

Spinal Cord Injury Treatment and Symptoms
XXXXXX #9669; Spinal Cord Injury treatment mdash; Finding the right information about Spinal Cord Injury treatment symptoms, is crucial to managing Spinal Cord Injur...

By: MainMDcom

See the article here:
Spinal Cord Injury ¦ Treatment and Symptoms - Video

Recommendation and review posted by sam

LONDON (SHARECAST) - ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy.

The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council.

The first award of 0.4m will be used for ReNeurons ReN009 stem cell therapy candidate for critical limb ischaemia, a severe blockage in the arteries which markedly reduces blood-flow to the extremities including hands, feet and legs.

The second award of 0.8m relates to the company's ReN003 stem cell candidate for the treatment of retinitis pigmentosa, an eye disease in which there is damage to the retina.

Michael Hunt, the Chief Executive Officer of ReNeuron, said: "We are delighted to have been successful in winning the two grants we applied for in the current round of the Biomedical Catalyst funding competition.

"This highly competitive scheme involves a rigorous peer review of applicants' technologies and commercial development plans.

"In common with other awardees, we therefore regard the grants as representing a strong independent endorsement of ReNeuron's world-class stem cell development capabilities which we hope will eventually lead to the wide-scale treatment of disease conditions where there is currently a very large unmet medical need."

Shares rose 0.86% to 2.94p at 08:52 Monday.

RD

See more here:
ReNeuron Group wins grants for stem cell therapy development

Recommendation and review posted by simmons

PORT ST. LUCIE, Fla.--(BUSINESS WIRE)--

Scientists at the Vaccine & Gene Therapy Institute of Florida (VGTI Florida), a nonprofit immunological research institute, published a paper in the March 10th issue of Nature Medicine that reveals a major defect in a particular T cell subset, the follicular helper T cells, that is a component in the response to vaccines. Elias K. Haddad, Ph.D., Associate Member and Rafael Cubas, Ph.D., both from VGTI Florida, and their colleagues from the US and Europe, showed that previously unidentified dysfunction of these cells might have major implications on the ability of HIV infected patients to respond to vaccines.

Antibodies, which are secreted by B cells, are among the most effective weapons against infectious diseases such as HIV, influenza, and the common cold as they are the major therapeutic components that are produced in response to vaccines. Follicular helper T cells are the major inducers of this antibody response. The majority of HIV infected individuals fail to produce protective antibodies and therefore, have diminished responses to immunizations. Dr. Haddad and colleague identified components of the mechanism that are impaired during HIV infection. These results provide important insight into HIV pathogenesis and pave the way to the development of novel anti HIV therapies.

Dr. Haddad and his colleagues contend that the results of this investigation will have important implications for the design of novel vaccines and therapies against HIV infection. Dr. Haddad said, Targeting follicular helper T cells in vaccine development may lead to the design of more effective vaccines for HIV.

About VGTI Florida

VGTI Florida is a leading immunological research institute that is on an urgent mission to transform scientific discoveries into novel treatments and cures for devastating chronic illnesses such as cancer, HIV/AIDS, and infectious diseases. VGTI Florida is an independent non-profit 501(c)(3) organization located in the Tradition Center for Innovation in Port St. Lucie, Florida. For more information, please visit http://www.VGTIFL.org.

Read more from the original source:
VGTI Florida Scientists Reveal a Mystery of Diminished Immune Function in HIV Infection

Recommendation and review posted by Bethany Smith

TORONTO, March 5, 2013 /CNW/ - Some of the dramatic differences seen among patients with schizophrenia may be explained by a single gene that regulates a group of other schizophrenia risk genes. These findings appear in a new study from the Centre for Addiction and Mental Health (CAMH).

The study revealed that people with schizophrenia who had a particular version of the microRNA-137 gene (or MIR137), tended to develop the illness at a younger age and had distinct brain features - both associated with poorer outcomes - compared to patients who did not have this version. This work, led by Drs. Aristotle Voineskos and James Kennedy, appears in the latest issue of Molecular Psychiatry.

Treating schizophrenia is particularly challenging as the illness can vary from patient to patient. Some individuals stay hospitalized for years, while others respond well to treatment.

"What's exciting about this study is that we could have a legitimate answer as to why some of these differences occur," explained Dr. Voineskos, a clinician-scientist in CAMH's Campbell Family Mental Health Research Institute. "In the future, we might have the capability of using this gene to tell us about prognosis and how a person might respond to treatment."

"Drs. Voineskos and Kennedy's findings are very important as they provide new insights into the genetic basis of this condition that affects thousands of Canadians and their families," says Dr. Anthony Phillips, Scientific Director at the Canadian Institutes of Health Research Institute of Neurosciences, Mental Health and Addiction.

Also, until now, sex has been the strongest predictor of the age at which schizophrenia develops in individuals. Typically, women tend to develop the illness a few years later than men, and experience a milder form of the disease.

"We showed that this gene has a bigger effect on age-at-onset than one's gender has," said Dr. Voineskos, who heads the Kimel Family Translational Imaging-Genetics Research Laboratory at CAMH. "This may be a paradigm shift for the field."

The researchers studied MIR137 a gene involved in turning on and off other schizophrenia-related genes in 510 individuals living with schizophrenia. The scientists found that patients with a specific version of the gene tended to develop the illness at a younger age, around 20.8 years of age, compared to 23.4 years of age among those without this version.

"Although three years of difference in age-at-onset may not seem large, those years are important in the final development of brain circuits in the young adult," said Dr. Kennedy, Director of CAMH's Neuroscience Research Department. "This can have major impact on disease outcome."

In a separate part of the study involving 213 people, the researchers used magnetic resonance brain imaging (MRI) and diffusion tensor-MRI (DT-MRI). They found that individuals with the particular gene version tended to have unique brain features. These features included a smaller hippocampus, which is a brain structure involved in memory, and larger lateral ventricles, which are fluid-filled structures associated with disease outcome. As well, these patients tended to have more impairment in white matter tracts, which are structures connecting brain regions, that serve as the information highways of the brain.

Originally posted here:
Single gene might explain why people with schizophrenia have such different outcomes, according to a new CAMH imaging ...

Recommendation and review posted by Bethany Smith

Study: Genital warts are the most common symptom of HPV infection in the U.S. Military. polyDNA recommends Gene-Eden-VIR against the Human Papillomavirus.

Rochester, NY (PRWEB) March 10, 2013

The Massachusetts Society for Medical Research says in a new study that HPV genital warts among service members in the military is the most common sexually transmitted infection. The researchers examined the annual incidence of diagnoses of genital warts (GW) among U.S. service members before and after the availability of the quadrivalent HPV (HPV4) vaccine in 2006. According to this same study, Incidence rates of GW diagnoses markedly declined among female service members in the HPV4 vaccine-eligible age range from 2007 (following introduction of the HPV4 vaccine) through 2010.

polyDNA points out that HPV is actually the most common sexually transmitted infection in the general population. In fact, according to the CDC, over 20 million people in the U.S. are infected with the Human Papillomavirus. Since HPV is transmitted through any skin-to-skin contact, one can get infected without having sex.

Thats why many young people call HPV, stuff that gets up around the sides of condoms.

Moreover, in some individuals the HPV establishes a lifelong infection. However, infected individual can avoid the symptoms, and help prevent spreading the infection to other people. How? By lowering the load of latent viruses in the infected individual.

The key to your health is to reduce the level of the latent viruses in your body to harmless levels. Dr. Hanan Polansky

Although the CDC says that in 90% of cases, the bodys immune system clears HPV naturally within two years, sometimes the body has trouble clearing the virus. In these instances, symptoms such as genital warts or dangerous cervical changes can occur.

Gene-Eden-VIR is the only scientifically based, all natural, herbal supplement with scientific studies published in the U.S. National Library of Medicine and National Institutes of Health. It has been specifically designed and formulated to boost the body's own immune system in order to counter many of the latent viruses of today, including the Genital Warts virus.

The truth is, Gene-Eden-VIR is really efficient against the latent version of the virus that causes genital warts; each ingredient was chosen through a scientific approach. PolyDNA scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world in order to identify the safest, most effective natural ingredients that target the latent (sleeping)HPV Virus.

Read more:
Study: HPV Genital Warts is Most Common Sexually Transmitted Infection in U.S. Military, polyDNA Recommends Gene -Eden ...

Recommendation and review posted by Bethany Smith

Mar. 10, 2013 The British astrophysicist Stephen Hawking is likely to be the world's most famous person living with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. ALS is a progressive disease affecting motor neurons, nerve cells that control muscle function, and nearly always leads to death. Researchers at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna have now identified a completely new mechanism in the onset of motor neuron diseases. Their findings could be the basis for future treatments for these presently incurable diseases.

A new principle on motor neuron death

The IMBA scientists, working with an international team of researchers under the leadership of Josef Penninger and Javier Martinez, discovered a completely new fundamental mechanism that triggers the death of motor neurons. Motor neurons are nerve cells responsible for stimulating muscles. The loss of these motor neurons in mice with a genetic mutation in a gene named CLP11 leads to severe and progressive muscular paralysis and, in some cases, to death.

"We've been working on resolving the function of the CLP1 gene in a living organism for a long time. To do that, we developed model mice in which the function of CLP1 was genetically inactivated. To our utter surprise we discovered that deactivating CLP1 increases the sensitivity of cell die when exposed to oxidative stress2. That leads to enhanced activity of the p53 protein3 and then to the permanent destruction of motor neurons," says Toshikatsu Hanada, a postdoctoral researcher working in the lab of Josef Penninger and first author of the study along with Stefan Weitzer.

Stephen Hawking -- a most renowned patient

Motor neuron diseases (MNDs), such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA), are chronic disorders of the neuromuscular system. These diseases are caused by damage in the motor nerve cells in the brain and spinal cord, and the nerves can no longer stimulate motion in the muscles. The primary symptoms are muscular weakness, muscular dystrophy, and problems swallowing or speaking. Stephen Hawking was diagnosed with ALS 50 years ago. But not all ALS patients live so long with the disease: so far there are no treatments for ALS. Nearly all ALS patients die of paralysis of respiratory muscles within a few years.

Completely new disease mechanism

Javier Martinez, an IMBA team leader and co-author of the study, is a specialist in the field of ribonucleic acid (RNA) research. His research group had discovered the CLP1 gene in an earlier study, published in Nature in 2007. Until now, the exact essential function of CLP1 in RNA biology was unclear. "By deactivating CLP1, we have discovered a previously unknown new species of RNA," says Javier Martinez about the scientific relevance of the work. "The accumulation of this RNA is a consequence of increased oxidative stress in the cell. We see this as one of the triggers for the loss of motor neurons that occurs in ALS and other neuromuscular diseases. Thus our findings describe a completely new mechanism of motor neuron diseases."

Seminal findings

Josef Penninger, scientific director at the IMBA and last-author of the study, is excited about the researchers' findings: "This surprising discovery of a role of CLP1 in the onset of motor neuron diseases is an entirely new principle in how RNA talks to oxidative stress. Nearly all genetic mutations found in ALS patients affect either RNA metabolism or oxidative stress, suggesting a possibly unifying principle for these diseases. Our work may have revealed the 'missing link' in how these two biological systems communicate and trigger incurable diseases like ALS."

See the original post here:
Mutated gene causes nerve cell death

Recommendation and review posted by Bethany Smith

Genetic Engineering OSCSS Bio Commercial
Genetic Engineering OSCSS Bio Commercial. OSCSS6219 videos. Subscribe Subscribed Unsubscribe 6. 2 views. Like 0 Dislike 0. Like. Sign in to youtube. Sign in with your youtube Accountyoutube Google+ Gmail Orkut Picasa or Chrome to like OSCSS62s video. Sign in. I dislike this. Sign in to youtube. Sign in with your youtube Accountyoutube Google+ Gmail Orkut Picasa or Chrome to dislike OSCSS62s video. Sign in. About Share Add to. Sign in to youtube. Sign in with your youtube Accountyoutube ...

By: OSCSS62

See the original post:
Genetic Engineering OSCSS Bio Commercial - Video

Recommendation and review posted by Bethany Smith

Press TV: Threat of Aid Cuts to Israel - Jim W_ Dean002
Mark Robert 3 days ago. DNA Proof that 90% of Jews are 70% European Google or watch on #65279; You TubeJewish Genome Myth BUSTED. Research papers found here Dr Eran Israeli Elhaik exposes the DNA genome published by Oxford Journals 01162013 Title Google The Missing Link of Jewish European Ancestry mckusickNathans Institute of Genetic Medicine Johns Hopkins University School of Medicine Baltimore MD USA 21208. You cant be AntiSemitic against people who are 70% European ...

By: Gordon Duff

Read the original here:
Press TV: Threat of Aid Cuts to Israel - Jim W_ Dean002 - Video

Recommendation and review posted by Bethany Smith

Introducing FDZ Liquid: Flow Like Liquid - Episode 1 By: FDZ Hackyy
Thumbs up for this SICK new player! 😉 -Hackyy Song: Hendersin - Dear Hip Hop Player: https://www.youtube.com/user/Liquidattion Editor: https://www.youtube.c...

By: OfficialFDZ

See the article here:
Introducing FDZ Liquid: Flow Like Liquid - Episode 1 By: FDZ Hackyy - Video

Recommendation and review posted by Bethany Smith

PGM Third Lesson, First Swings
PGM Third Lesson, First Swings.

By: Mary Hashagen

Visit link:
PGM Third Lesson, First Swings - Video

Recommendation and review posted by Bethany Smith

PGM Third Lesson, Last Swings
PGM Third Lesson, Last Swings.

By: Mary Hashagen

Read the original here:
PGM Third Lesson, Last Swings - Video

Recommendation and review posted by Bethany Smith

DNA Genetics C13 Haze
It #39;s the debut of DNA Genetics C13 Haze, a leggy girl that requires plenty of space. This is a much better example of this marijuana strain than the last vid...

By: Matt Mernagh

Originally posted here:
DNA Genetics C13 Haze - Video

Recommendation and review posted by Bethany Smith

Epigenetics
Paul Andersen explains the concepts of genetics. He starts with a brief discussion of the nature vs. nurture debate and shows how epigenetics blurs this dist...

By: bozemanbiology

Read the original here:
Epigenetics - Video

Recommendation and review posted by Bethany Smith

FIRIN MAH LABIA (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Download Here: http://www.hidden-source.com What is The Hidden? "In the early 1950s human genetics e...

By: SeaNanners

Read more:
FIRIN MAH LABIA (The Hidden) - Video

Recommendation and review posted by Bethany Smith

Baby goes cross-eyed trying to find cereal puff
A baby goes cross-eyed trying to find her missing cereal. Whether it be their first step, first word or first wildly original dance move, toddletale is the c...

By: ToddleTale

Continue reading here:
Baby goes cross-eyed trying to find cereal puff - Video

Recommendation and review posted by Bethany Smith

DON #39;T CLOSE YOUR EYES! (The Hidden)
Enjoy the video? Subscribe! http://bit.ly/M0mU1V #9669; #9669; #9669; Download Here: http://www.hidden-source.com What is The Hidden? "In the early 1950s human genetics e...

By: SeaNanners

Read the original:
DON'T CLOSE YOUR EYES! (The Hidden) - Video

Recommendation and review posted by Bethany Smith